Cetuximab and panitumumab are effective epidermal growth factor receptor (EGFR) targeted agents for metastatic colorectal cancer (mCRC), but patients whose tumors have KRAS mutations except G13D [9] are generally believed to not benefit from these agents [10], [11]. Here, EGFR is linked to metastatic colorectal cancer.